Dyne Therapeutics (NYSE:DYN) Trading Up 11.8%

Dyne Therapeutics, Inc. (NYSE:DYNGet Free Report) traded up 11.8% during trading on Tuesday . The stock traded as high as $9.86 and last traded at $9.73. 27,483 shares traded hands during trading, a decline of 94% from the average session volume of 445,920 shares. The stock had previously closed at $8.70.

Wall Street Analyst Weigh In

DYN has been the topic of a number of analyst reports. Chardan Capital restated a “buy” rating and issued a $20.00 price objective on shares of Dyne Therapeutics in a report on Friday, August 4th. StockNews.com assumed coverage on Dyne Therapeutics in a research note on Thursday, October 5th. They issued a “sell” rating on the stock. Finally, JPMorgan Chase & Co. lifted their price target on Dyne Therapeutics from $20.00 to $22.00 and gave the stock an “overweight” rating in a report on Wednesday, August 9th. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $27.20.

Get Our Latest Stock Analysis on DYN

Dyne Therapeutics Stock Performance

The stock’s 50-day moving average is $8.63 and its 200 day moving average is $10.77. The stock has a market capitalization of $667.77 million, a PE ratio of -3.03 and a beta of 0.35.

Dyne Therapeutics (NYSE:DYNGet Free Report) last released its quarterly earnings data on Monday, October 30th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.16). Analysts expect that Dyne Therapeutics, Inc. will post -3.73 earnings per share for the current year.

Insiders Place Their Bets

In other news, COO Susanna Gatti High sold 9,939 shares of Dyne Therapeutics stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $7.40, for a total value of $73,548.60. Following the transaction, the chief operating officer now directly owns 94,605 shares of the company’s stock, valued at approximately $700,077. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 17,243 shares of company stock valued at $145,621 over the last quarter. Company insiders own 32.89% of the company’s stock.

Hedge Funds Weigh In On Dyne Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. grew its stake in shares of Dyne Therapeutics by 26.8% in the 2nd quarter. BlackRock Inc. now owns 3,322,187 shares of the company’s stock valued at $37,375,000 after purchasing an additional 702,966 shares during the last quarter. Wasatch Advisors LP increased its stake in Dyne Therapeutics by 16.2% in the 1st quarter. Wasatch Advisors LP now owns 2,927,278 shares of the company’s stock valued at $33,722,000 after buying an additional 407,699 shares during the period. Deep Track Capital LP raised its position in Dyne Therapeutics by 7.1% during the 2nd quarter. Deep Track Capital LP now owns 2,499,912 shares of the company’s stock worth $28,124,000 after buying an additional 165,279 shares during the last quarter. VR Adviser LLC acquired a new stake in shares of Dyne Therapeutics in the 2nd quarter worth $24,457,000. Finally, Goldman Sachs Group Inc. lifted its stake in shares of Dyne Therapeutics by 34.5% in the 2nd quarter. Goldman Sachs Group Inc. now owns 2,009,529 shares of the company’s stock worth $22,607,000 after acquiring an additional 515,079 shares during the period. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

(Get Free Report)

Dyne Therapeutics, Inc, a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

Read More

Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.